Video

Dr. Shirasu on the Design for the GALAXY Trial Examining ctDNA in CRC

Hiromichi Shirasu, MD, discusses the design of the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Hiromichi Shirasu, MD, of the Shizuoka Cancer Center in Shizuoka, Japan, discusses the design of the GALAXY trial (UMIN000039205), part of the CIRCULATE-Japan project, which is examining circulating tumor DNA (ctDNA) in patients with resectable colorectal cancer (CRC).

GALAXY is a prospectively-conducted, large-scale, registry designed to monitor ctDNA status in patients with stage II to stage IV CRC who are undergoing surgical resection, according to Shirasu. Blood samples will be collected from patients before they undergo surgery, as well as at 4, 12, 24, 36, 48, 72, and 96 weeks after resection, Shirasu says. Additionally, computed tomography scans will be conducted every 6 months after surgery for 7 years, Shirasu adds.

Once results from the assay are received, patients can then be considered for enrollment to the phase 3 VEGA trial, which will assess observation vs adjuvant capecitabine plus oxaliplatin in patients from the GALAXY study who have high-risk stage II disease or low-risk stage III disease; or the phase 3 ALTAIR trial (NCT02305238), which will evaluate the superiority of trifluridine/tipiracil vs placebo in GALAXY participants with ctDNA status that remains positive after the standard therapy, Shirasu explains. Additional samples will also be collected for assessment, and a total of 2500 patients will be enrolled to the study, Shirasu concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity